Impact of Different BRCA1/2 Gene Variants on Therapy Response and Prognosis in Ovarian Cancer An Observational Study by IRCCS Azienda Ospedaliero-Universitaria di Bologna

What this Trial Is About

Researchers are studying ovarian cancer patients with specific changes in the BRCA1 and BRCA2 genes to understand how these gene variants affect response to chemotherapy and overall survival. Ovarian cancer is the leading cause of death among gynecological cancers and is often diagnosed late, leading to poor survival rates. The study aims to stratify patients based on their BRCA gene status to help develop more personalized and effective treatments. The study focuses on patients diagnosed with ovarian cancer who have tested positive for BRCA1 or BRCA2 gene alterations. These patients have been followed or treated at specialized oncology departments in Bologna, Italy. Treatment typically includes surgery and platinum-based chemotherapy, with maintenance therapies like PARP inhibitors being more effective in patients with BRCA alterations. The study evaluates differences in drug response and survival over a 12-month period. Participants' medical history, BRCA testing results, and treatment outcomes are assessed to measure differences in response to chemotherapy. Researchers will monitor predictive responses based on BRCA1/2 status for a year. The study excludes certain ovarian cancer types such as mucinous or borderline tumors to focus on relevant cases. The findings aim to improve personalized treatment approaches for ovarian cancer patients with BRCA mutations.

Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer